###### Strengths and limitations of this study

-   This is the first systematic review that has examined the incidence and prognostic impacts of bleeding complications post acute coronary syndrome (ACS) within the outpatient setting.

-   The review combined evidence from observational studies and randomised controlled trials involving a total of 714 458 participants for the primary objectives and 187 317 for the secondary objectives.

-   The studies included in the review were heterogeneous in regard to bleeding definition, the ACS presentation, demographic characteristics of the study participants, severity and type of bleeding examined, length of follow-up, discharged antiplatelet and anticoagulant regimens, therefore we were unable to pool data quantitatively.

-   The findings in relation to major adverse cardiovascular events and rehospitalisation should serve as hypothesis generating due to limited data.

Introduction {#s1}
============

The management of acute coronary syndrome (ACS) depends on the clinical presentation, with an overall aim of reducing myocardial ischaemia and adverse ischaemic events.[@R1] This goal is fundamentally achieved via therapy with a combination of antithrombotic and invasive strategies. Paradoxically, these management strategies while achieving the desired goal of reducing ischaemic events increases the risk of bleeding complications.[@R2] In the clinical trial setting, the incidence of major bleeding is reported to be between 1% and 10% depending on the bleeding definition used,[@R5] with observational studies reporting incidences of between 2.8%[@R8] and 11%.[@R9] However, the emphasis in the majority of these studies has been on major in-hospital or 30-day bleeding events (a composite of in-hospital and postdischarge events), with little consideration for events in the long term after hospital discharge. Post hospital discharge, patients with ACS may remain on dual antiplatelet therapy for up to a year, and aspirin indefinitely, so their risk of bleeding complications persist in the long term.

Major bleeding is an independent predictor of adverse outcomes, including mortality, recurrent myocardial infarction (MI), stroke, and stent thrombosis in patients with ACS.[@R5] The association between major in-hospital bleeding events and adverse outcomes (most notably mortality) appeared to be maintained regardless of the definition of bleeding used.[@R5] These adverse events do, however, appear to depend on the anatomic site of the bleed,[@R15] and the site of bleeding may vary between the in-hospital and the postdischarge settings. While the nature of in-hospital bleeds and their association with adverse events has been well described, the timing, types and association of bleeding events that occur late after hospital discharge with clinical outcomes such as mortality is unclear.

To date, there has not been a systematic review of the incidence, types, and prognostic impact of bleeding events post hospital discharge for ACS. The primary objective of this systematic review was therefore to determine the incidence, timing, and types of post hospital discharge bleeds within the adult post-ACS population. The secondary objective was to determine the association of postdischarge bleeds with mortality, major adverse cardiovascular events (MACE), rehospitalisation and re-infarction in the outpatient setting.

Methods {#s2}
=======

Eligibility criteria {#s2a}
--------------------

There were two linked objectives for the systematic review. For the primary objective, we selected studies that reported on the incidence, timing, and types of bleeding post-ACS post hospital discharge. For the secondary objective, we included studies that compared patients with versus those without bleeding post-ACS post hospital discharge in relation to mortality, MACE, myocardial re-infarction and rehospitalisation. We only included randomised controlled trials (RCTs) where bleeding events were reported as secondary or safety outcomes, and observational studies which were published in English. Studies where the intervention was coronary artery bypass graft surgery or elective percutaneous coronary intervention (PCI) were excluded. We also excluded studies where the study population comprised patients with stable angina or other coronary artery disease. See [table 1](#T1){ref-type="table"} for detailed inclusion and exclusion criteria for the review. For studies using the same data source, only one was included in the review, based on: (1) quality, and then by (2) sample size, followed by (3) length of follow-up, unless the studies reported on different outcomes.

###### 

Inclusion and exclusion criteria specific to primary and secondary objectives

  Inclusion criteria                                                                                             Exclusion criteria
  -------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------
  **Primary objective**                                                                                          
   Participants aged 18 years and over                                                                           ✓Cannot be ascertained whether bleed occurred in-hospital or postdischarge
   Participants discharged with an ACS diagnosis (UA or STEMI or NSTEMI) at index hospitalisation                ✓In-hospital bleeds only
   Randomised controlled trial or observational study                                                            ✓Incidence and 95% CI or number of bleeding events cannot be extracted or calculated
   Bleeding occurred after hospital discharge                                                                    ✓Study population combined patients with ACS and other coronary diseases such as stable angina
   Any type of bleeding examined (such as gastrointestinal bleed) post hospital discharge for ACS                ✓Postdischarge bleeding after PCI, without specifying the clinical presentation for the PCI or whether the PCI was elective
   Incidence and associated 95% CI can be extracted or calculated                                                ✓Only reporting CABG-related bleeds
                                                                                                                 ✓Conference/study abstracts, editorials and reviews
  **Secondary objective**                                                                                        
   Participants aged 18 years and over                                                                           ✓Cannot be ascertained whether bleed occurred in-hospital or postdischarge
   Participants discharged with an ACS diagnosis (UA or STEMI or NSTEMI) at index hospitalisation                ✓In-hospital bleeds only
   Randomised controlled trial or observational study                                                            ✓Study population combined patients with ACS and other coronary diseases such as stable angina
   Bleeding occurred after hospital discharge                                                                    ✓Postdischarge bleeding after PCI, without specifying the clinical presentation for the PCI or whether the PCI was elective
   Evaluated outcome of or composite of mortality, MI, rehospitalisation and MACE in bleed vs no bleed cohorts   ✓Only reporting CABG-related bleeds
                                                                                                                 ✓Conference/study abstracts, editorials and reviews

ACS, acute coronary syndrome; CABG, coronary artery bypass graft; MACE, major adverse cardiovascular event; MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; UA, unstable angina.

Search strategy {#s2b}
---------------

Medline (Healthcare Databases Advanced Search (HDAS); 1946--August 2018), Embase (Ovid SP; 1974--August 2018), Amed (Ovid SP; 1985--August 2018) and Central (Cochrane central register of controlled trials) were searched up to August 2018 using a search strategy which combined keywords and related database-specific subject headings for both primary and secondary objectives (see online [supplementary table 1](#SP1){ref-type="supplementary-material"} for the full search strategy used on the Embase database). The *Journal of the American College of Cardiology (JACC)*, the *European Heart Journal*, *Heart*, and *Circulation* were electronically searched for relevant articles and grey literature. The bibliographies of included studies and relevant review articles identified from each database were scrutinised for additional relevant articles. Citation tracking of included studies via Web of Science was carried out to retrieve additional relevant articles.

10.1136/bmjopen-2018-023337.supp1

Study selection {#s2c}
---------------

The titles of all identified articles were screened and those which were obviously irrelevant were eliminated at this stage. The abstracts of the remaining articles were screened independently by NI and JP. Discordances were resolved by consensus between NI, JP and MAM. The full texts of the remaining articles were then screened by NI, with JP also screening 1 in 10.

Data extraction {#s2d}
---------------

We extracted study characteristics including study design, setting, length of follow-up, in-hospital interventions, participant characteristics, discharged therapy and comorbidities. The outcomes of incidence of postdischarge bleeding and associated 95% CIs, time of bleed, location/type of bleed, and the adjusted and unadjusted associations of bleeding with mortality, MACE, re-infarction and rehospitalisation were extracted from individual studies onto a prepiloted and formatted spreadsheet. In studies where incidence and associated 95% CIs were not reported but relevant data were available, incidence per 100 persons at risk were calculated (ie, essentially as a proportion). For studies that combined in-hospital and postdischarge bleeds, and episodes of bleeds were stratified by time (for instance at 30 days, 6 months, 12 months), bleeds that occurred within the initial 30 days were considered to be in-hospital bleeds (decided by consensus of NI, KJP, MAM and UTK) and therefore removed from the numerator and denominator. The authors of original studies were contacted where necessary data were missing or to confirm methodological aspects or other characteristics of the study.

Quality assessment {#s2e}
------------------

Observational studies and post hoc observational analyses of RCTs were appraised by the Newcastle Ottawa Scale (NOS) for assessing risk of bias in non-randomised studies.[@R16] The NOS quality assessment scale contains eight items partitioned into three categories of selection, comparability and outcome. A maximum of one star is allocated to a high-quality study for each item under selection and outcome and a maximum of two stars under comparability, giving an overall maximum of nine stars. We considered studies with an overall number of stars greater than or equal to six stars as high-quality studies.[@R17] RCTs were appraised by the Scottish Intercollegiate Guideline Network quality assessment tool.[@R18] Each study was categorised as high quality, acceptable quality or low quality based on the standard criteria for this tool. Quality assessment was based on the primary objective of each study as incidence of bleeding was typically reported as safety or secondary outcome measure.

Data synthesis {#s2f}
--------------

A narrative synthesis approach was applied due to heterogeneity in relation to length of follow-up, ACS presentation, definition of bleeding used, type of bleeding examined, severity of bleeding examined, geographical location and discharge therapy across studies. For the primary objective, the narrative synthesis was carried out in stages. Initially, the incidence of bleeding overall was summarised separately for observational studies and RCTs. The incidence of bleeding was then stratified by ACS presentation (ST-elevation myocardial infarction \[STEMI\], non-ST-elevation myocardial infarction/unstable angina \[NSTEMI/UA\]) and discharge antithrombotic drug combinations and duration (single antiplatelet \[SAPT\], dual antiplatelet \[DAPT\] and receipt of oral anticoagulant) in studies that reported these. To assess the incidence of bleeding by time from hospital discharge, the incidence of bleeding was stratified by follow-up time within studies which looked at multiple time periods. Where studies allowed, the incidence of bleeding stratified by major, minor and nuisance bleeds (see online [supplementary table 2](#SP1){ref-type="supplementary-material"} for definitions), and the incidence of different types of bleeding events were examined.

We assessed the strength of evidence (SOE) for each secondary outcome following the Agency for Healthcare Research and Quality guideline.[@R19] For each secondary outcome, assessment was carried out by examining risk of bias, consistency, directness and precision across studies that reported on this outcome, and a grade allocated as high, moderate, low or insufficient based on these assessments.

Patient and public involvement {#s2g}
------------------------------

Patients and members of the public did not have any role in the design, conduct, data synthesis or reporting of the study.

Results {#s3}
=======

The search of Medline, Embase, Amed and Central (Cochrane) identified 37 studies,[@R20] 4 studies were further identified from electronic search of *JACC* database,[@R3] 2 from Web of Science citation index,[@R60] 9 from bibliographic screening of included studies,[@R4] and finally, 1 from recommendation by an expert within the field.[@R70] Overall, 53 studies (36 observational studies and 17 RCTs) were included in the review with a combined cohort of 714 458 participants for the primary objectives and 187 317 for the secondary objectives ([figure 1](#F1){ref-type="fig"}). Of the 53 studies, 45 only reported on the primary outcomes, 3 only reported on the secondary outcomes and 5 reported on both primary and secondary outcomes.

![Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart depicting steps involved in selecting or rejecting studies for inclusion in the review.](bmjopen-2018-023337f01){#F1}

Characteristics of included studies {#s3a}
-----------------------------------

The characteristics of included studies (for the primary objective) are summarised in [table 2](#T2){ref-type="table"} for observational studies and [table 3](#T3){ref-type="table"} for RCTs. Overall, 50 studies reported on the primary outcome, of which 68% (n=34) were cohort studies and 32% (n=16) were RCTs. The characteristics of included studies for the secondary objective are summarised in [table 4](#T4){ref-type="table"}. Overall, eight studies reported on the secondary outcomes, of which seven were cohort studies and one was an RCT.

###### 

Summary of observational studies included in the review by length of follow-up, bleeding definition used and in-hospital management strategy

  Primary author                     Location          Setting     Study design           Length of follow-up   Bleeding criteria                                                                In-hospital management strategy   N         Participants with bleed (n)   Crude incidence of bleeding per 100 persons and 95% CI   Quality score
  ---------------------------------- ----------------- ----------- ---------------------- --------------------- -------------------------------------------------------------------------------- --------------------------------- --------- ----------------------------- -------------------------------------------------------- ---------------
  Cuisset *et al* [@R29]             France            Inpatient   Prospective cohort     1 month               TIMI major/minor                                                                 PCI                               597       16                            2.68 (1.66 to 4.31)\*                                    2
  Braun *et al* [@R26]               Sweden            Registry    Retrospective cohort   3 months              BARC 2--5                                                                        PCI                               263       26                            9.89 (6.84 to 14.1)\*                                    5
  Amin *et al* [@R21]                USA               Registry    Retrospective cohort   6 months              BARC 1--5                                                                        PCI                               9290      2246                          24.2 (23.3 to 25.1)\*                                    5
  Amin *et al* [@R20]                USA               Registry    Retrospective cohort   12 months             BARC 1                                                                           PCI                               3560      1335                          37.5 (35.9 to 39.1)\*                                    4
  Lattuca *et al* [@R36]             France            Inpatient   Prospective cohort     12 months             BARC 1--3                                                                        PCI                               369       132                           35.8 (31.1 to 40.8)\*                                    5
  Bacquelin *et al* [@R22]           France            Registry    Prospective cohort     12 months             BARC 2--5                                                                        PCI                               1006      79                            7.85 (6.35 to 9.68)\*                                    5
  Palmerini *et al* [@R59]           Multicentre       Unclear     Prospective cohort     12 months             BARC (any)                                                                       PCI                               1053      41                            3.91 (2.89 to 5.26)\*                                    5
  Kassaian *et al* [@R33]            Iran              Registry    Prospective cohort     12 months             GUSTO mild, moderate, severe                                                     NR                                1640      23                            1.40 (0.94 to 2.10)\*                                    4
  Yetgin *et al* [@R54]              The Netherlands   Registry    Cohort                 12 months             TIMI major                                                                       PCI                               2443      23                            0.94 (0.63 to 1.41)\*                                    5
  Fosbol *et al* [@R30]              USA               Registry    Prospective cohort     12 months             Bleed leading to hospitalisation                                                 NR                                7619      928                           12.2 (11.5 to 12.9)\*                                    6
  Tsai *et al* [@R85]                Taiwan            Registry    Retrospective cohort   12 months             Gastrointestinal bleed                                                           NR                                3580      273                           7.63 (6.80 to 8.54)\*                                    5
  Garay *et al* [@R70]               Spain             Registry    Retrospective cohort   12 months             Bleed leading to hospitalisation, transfusion or suspension of antithrombotics   NR                                1375      69                            5.02 (3.98 to 6.30)\*                                    3
  Garay *et al* [@R55]               Multicentre       Registry    Cohort                 12 months             Intracranial bleeding or bleed leading to hospitalisation or transfusion         PCI                               15 401    489                           3.18 (2.91 to 3.46)\*                                    5
  Effron *et al* [@R50]              USA               Registry    Retrospective cohort   12 months             Bleed leading to hospitalisation or transfusion                                  PCI                               15 788    492                           3.12 (2.86 to 3.40)\*                                    4
  Brinkert *et al* [@R47]            Canada            Registry    Cohort                 12 months             Hospitalisation with major bleeding                                              PCI, angiography, medically       22 312    588                           2.72 (2.51 to 2.94)\*                                    5
  Ko *et al* [@R68]                  Canada            Registry    Cohort                 12 months             Bleed leading to hospitalisation                                                 PCI                               8672      230                           2.65 (2.33 to 3.01)\*                                    6
  Boggon *et al* [@R25]              UK                Registry    Retrospective cohort   12 months             Any bleeding in patient GPRD or HES record                                       NR                                7543      NR                            11.4 (10.4 to 12.6)†                                     5
  Carrero *et al* [@R28]             Sweden            Registry    Prospective cohort     12 months             Major bleed                                                                      NR                                36 001    333                           0.92 (0.83 to 1.03)\*                                    7
  Graipe *et al* [@R31]              Sweden            Registry    Prospective cohort     12 months             Intracranial bleed                                                               NR                                187 386   590                           0.32 (0.30 to 0.34)                                      6
  Wang *et al* [@R44]                USA               Registry    Cohort                 12 months             Haemorrhagic stroke                                                              NR                                169 863   335                           0.20 (0.18 to 0.22)                                      5
  Barra *et al* [@R23]               Portugal          Inpatient   Prospective cohort     13.4 months (mean)    TIMI/GUSTO major criteria                                                        NR                                852       60                            7.04 (5.51 to 8.96)\*                                    3
  Sra *et al* [@R41]                 Canada            Inpatient   Prospective cohort     15 months             BARC 1--5                                                                        PCI                               2034      440                           21.6 (19.9 to 23.5)\*                                    5
  Caneiro-Queija *et al* [@R48]      Spain             Registry    Cohort                 455 days (median)     BARC 2--3                                                                        PCI                               4229      500                           11.8 (10.9 to 12.8)\*                                    6
  Sørensen *et al* [@R40]            Denmark           Registry    Prospective cohort     476.5 days (mean)     Fatal and non-fatal bleed                                                        PCI                               40 812    1967                          4.82 (4.62 to 5.03)\*                                    5
  Raposeiras-Roubín *et al* [@R52]   Multicentre       Registry    Cohort                 17.2 months (mean)    BARC 3 or 5                                                                      PCI                               4310      66                            1.53 (1.21 to 1.94)\*                                    6
  Cuschieri *et al* [@R61]           USA               Registry    Retrospective cohort   1.7 years (mean)      Gastrointestinal bleed                                                           NR                                3218      107                           3.33 (2.76 to 4.00)\*                                    4
  Wong *et al* [@R45]                UK                Inpatient   Retrospective cohort   21 months             CURE major/life threatening                                                      NR                                224       15                            6.70 (4.10 to 10.8)\*                                    4
  Buresly *et al* [@R62]             Canada            Registry    Cohort                 654 days (mean)       Bleed leading to hospitalisation                                                 NR                                21 443    1428                          6.66 (6.33 to 7.00)\*                                    3
  Voss *et al* [@R43]                New Zealand       Registry    Cohort                 1.94 years (mean)     Other                                                                            NR                                3666      206                           5.88 (5.15 to 6.71)\*                                    4
  Brener *et al* [@R57]              USA and Germany   Registry    Prospective cohort     24 months             TIMI, GUSTO and ACUITY Major bleed                                               PCI                               8582      430                           5.17 (4.71 to 5.66)\*                                    5
  Ertaş *et al* [@R51]               Turkey            Registry    Cohort                 24 months             Physician-confirmed bleeding event                                               NR                                1010      21                            2.08 (1.36 to 3.16)\*                                    4
  Blin *et al* [@R46]                France            Registry    Cohort                 3 years               Hospitalisation with bleeding                                                    NR                                1585      49                            3.09 (2.35 to 4.06)\*                                    5
  Chamberlain *et al* [@R27]         USA               Registry    Cohort                 4.3 years             Other                                                                            NR                                1159      312                           26.9 (24.5 to 29.6)\*                                    6
  Kazi *et al* [@R69]                USA               Registry    Retrospective cohort   4.42 years (mean)     Major spontaneous bleeding                                                       PCI                               22 527    368                           1.63 (1.48 to 1.81)\*                                    5

\*Incidence and associated 95% CI calculated from data within study.

†Incidence and associated 95% CI reported within study per 100 person years.

ACUITY, acute catheterisation and urgent intervention triage strategy; AMI, acute myocardial infarction; BARC, Bleeding Academic Research Consortium; CURE, clopidogrel in unstable angina to prevent recurrent events; GPRD, General Practice Research Database; GUSTO, global use of strategies to open occluded arteries; HES, hospital episodes statistics; NR, not reported; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.

###### 

Summary of randomised controlled trials included in the review by length of follow-up, bleeding definition used and in-hospital management strategy

  Primary author             Location          Trial                 Study design               Length of follow-up   Bleeding criteria        In-hospital management strategy   N        Participants with bleed   Crude incidence of bleeding per 100 persons and 95% CI   Quality score
  -------------------------- ----------------- --------------------- -------------------------- --------------------- ------------------------ --------------------------------- -------- ------------------------- -------------------------------------------------------- ---------------
  Yusuf *et al* [@R56]       Multicentre       OASIS-5               RCT                        6 months              OASIS-5 major            NR                                20 078   357                       1.84 (1.66 to 2.03)\*                                    High
  Jolly *et al* [@R4]        Multicentre       CURE                  Post hoc analysis of RCT   8 months              CURE major               PCI                               2658     28                        1.07 (0.74 to 1.54)\*                                    6†
  Khan *et al* [@R34]        Multicentre       APPRAISE-2            Post hoc analysis of RCT   240 days (median)     Any bleeding event       NR                                7392     506                       7.32 (6.73 to 7.96)\*                                    7†
  Carrabba *et al* [@R63]    Italy             BLESS                 RCT                        12 months             BARC 1--3                PCI                               193      76                        39.4 (32.8 to 46.4)\*                                    Acceptable
  Cuisset *et al* [@R49]     France            TOPIC                 RCT                        12 months             BARC≥2                   PCI                               634      106                       16.7 (14.0 to 19.8)\*                                    Low
  Han *et al* [@R32]         China             BRIGHT                RCT                        12 months             BARC 1--5                PCI                               2194     47                        2.33 (1.76 to 3.08)\*                                    Acceptable
  Savonitto *et al* [@R42]   Italy             Italian Elderly ACS   RCT                        12 months             BARC 2, 3a and 3b        NR                                313      3                         0.96 (0.33 to 2.78)\*                                    Acceptable
  Mrdovic *et al* [@R38]     Serbia            RISK-PCI              Post hoc analysis of RCT   12 months             TIMI major/minor         PCI                               2045     25                        1.29 (0.87 to 1.89)\*                                    5†
  Atar *et al* [@R60]        Multicentre       OPUS-TIMI 16          Post hoc analysis of RCT   12 months             Gastrointestinal bleed   NR                                10 288   104                       1.02 (0.84 to 1.24)\*                                    5†
  Kohli *et al* [@R35]       Multicentre       TRITON-TIMI 38        Post hoc analysis of RCT   15 months             TIMI major/minor         PCI                               12 674   407                       3.23 (2.94 to 3.56) \*                                   7†
  Mahaffey *et al* [@R37]    Multicentre       TRACER                Post hoc analysis of RCT   502 days (median)     TIMI major/minor         NR                                11 368   236                       2.12 (1.87 to 2.41)\*                                    6†
  Yeh *et al* [@R3]          USA               DAPT                  RCT                        18 months             BARC 2--5                PCI                               3576     111                       3.10 (2.58 to 3.72)\*                                    Acceptable
  Costa *et al* [@R66]       Italy             PRODIGY               Post hoc analysis of RCT   24 months             BARC 2--5                PCI                               1465     82                        5.60 (4.53 to 6.89)\*                                    5†
  Bonaca *et al* [@R67]      Multicentre       PEGASUS-TIMI 54       RCT                        33 months             TIMI major               NR                                21 162   435                       2.08 (1.89 to 2.28)\*                                    High
  Nikolsky *et al* [@R58]    Multicentre       HORIZON-AMI           Post hoc analysis of RCT   3 years               HORIZON major            PCI                               3602     63                        2.15 (1.68 to 2.74)\*                                    5†
  Bergen *et al* [@R24]      The Netherlands   ASPECT                RCT                        37 months             Major bleed              NR                                3404     99                        2.91 (2.39 to 3.53)\*                                    Low

\*Incidence and associated 95% CI calculated from data within study.

†Quality assessed by Newcastle Ottawa Scale.

APPRAISE-2, apixaban for prevention of acute ischaemic events; ASPECT, anticoagulants in the secondary prevention of events in coronary thrombosis; BARC, Bleeding Academic Research Consortium; BLESS, bleeding events and maintenance dose of prasugrel; BRIGHT, bivalirudin in acute myocardial infarction vs heparin and glycoprotein inhibitor plus heparin; CURE, clopidogrel in unstable angina to prevent recurrent events; DAPT, dual antiplatelet therapy study; HORIZON, harmonising otcomes with revascularisation and stents; HORIZON-AMI, harmonising outcomes with revascularisation and stents in acute myocardial infarction; GI, gastrointestinal; NR, not reported; OASIS-5, the fifth organisation to assess strategies in acute ischaemic syndromes; OPUS-TIMI 16, orbofiban in patients with unstable coronary syndrome-thrombolysis in myocardial infarction 16; PCI, percutaneous coronary intervention; PRODIGY, prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia; PEGASUS-TIMI 54, prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared with placebo on a background of aspirin thrombolysis in myocardial infarction 54; RCT, randomised controlled trial; RISK-PCI, risk scoring model to predict net adverse cardiovascular outcomes after primary percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction; TOPIC, timing of platelet inhibition after acute coronary syndrome; TRACER, thrombin receptor antagonist for clinical event reduction in acute coronary syndrome; TRITON-TIMI 38, trial to assess improvement in therapeutic outcomes by optimising platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38.

###### 

Summaries of risk of mortality, MACE and rehospitalisation from included studies by length of follow-up

  Primary author                                          Location          Setting    Length of follow-up   Bleeding criteria                           Adj/unadj outcomes                                                     Quality score                                                           
  ------------------------------------------------------- ----------------- ---------- --------------------- ------------------------------------------- ---------------------------------------------------------------------- ----------------------------------- ----------------------------------- -----
  Lamberts *et al* [@R64]                                 Denmark           Registry   12 months             Fatal and non-fatal bleed                   Adj HR 2.79 (95% CI 2.39 to 3.26)                                      NR                                  NR                                  7
  Brinkert *et al* [@R47]                                 Canada            Registry   12 months             Hospitalisation with major bleeding         Adj OR 2.97 (95% CI 1.71 to 5.15)                                      NR                                  NR                                  5
  Caneiro-Queija *et al* [@R48]                           Spain             Registry   455 days (median)     BARC 2--3                                   Adj HR 5.10 (95% CI 3.60 to 7.70)                                      NR                                  NR                                  6
  Brener *et al* [@R57]                                   USA and Germany   Registry   24 months             TIMI, GUSTO and ACUITY Major bleed          Bleeds between 30 and 365 days; unadj HR 4.61 (95% CI 1.70 to 12.49)   NR                                  NR                                  5
  Bleeds\>365 days; unadj HR 2.63 (95% CI 0.86 to 8.04)                                                                                                                                                                                                                                                 
  Schjerning Olsen *et al* [@R39]                         Denmark           Registry   3.5 years             Bleed leading to death or hospitalisation   Adj HR 1.51 (95% CI 1.28 to 1.79)                                      NR                                  NR                                  6
  Valgimigli *et al* [@R53]                               Multicentre       RCT        Unclear               BARC 1--3                                   BARC 1: adj HR 0.89 (95% CI 0.61 to 1.31)                              NR                                  NR                                  4\*
  BARC 2: adj HR 1.70 (95% CI 1.23 to 2.36)                                                                                                                                                                                                                                                             
  BARC 3a: adj HR 2.77 (95% CI 1.86 to 4.12)                                                                                                                                                                                                                                                            
  BARC 3b: adj HR 4.51 (95% CI 2.86 to 7.10)                                                                                                                                                                                                                                                            
  BARC 3c: adj HR 28.2 (95% CI 17.5 to 45.7)                                                                                                                                                                                                                                                            
  Sørensen *et al* [@R40]                                 Denmark           Registry   476.5 days (mean)     Fatal and non-fatal bleed                   NR                                                                     Adj HR 3.00 (95% CI 2.75 to 3.27)   NR                                  5
  Amin *et al* [@R20]                                     USA               Registry   12 months             BARC 1                                      NR                                                                     NR                                  Adj HR 1.20 (95% CI 0.95 to 1.52)   4

\*Quality assessed by Newcastle Ottawa Scale.

ACUITY, acute catheterisation and urgent intervention triage strategy; Adj, adjusted; BARC, Bleeding Academic Research Consortium; GUSTO, global use of strategies to open occluded arteries; MACE, major adverse cardiovascular event; NR, not reported; TIMI, thrombolysis in myocardial infarction; unadj, unadjusted.

Length of follow-up varied from 30 days[@R29] to just over 4 years[@R69] post hospital discharge. The number of participants ranged from 193 to 187 386. The definition for bleeding used by each study in the review are provided in online [supplementary table 2](#SP1){ref-type="supplementary-material"}. Some studies (n=23) did not report bleeding events based on recognised definitions (such as Bleeding Academic Research Consortium \[BARC\]). Of the included studies, 27 had specified the in-hospital ACS management strategy. In 26 of these studies, PCI was the baseline management strategy, and in one study the management strategy was a combination of PCI, angiography and medical therapy.

Risk of bias assessment {#s3b}
-----------------------

Summaries of risk of bias of individual studies are provided in [tables 2, 3 and 4](#T2 T3 T4){ref-type="table"}. Sixty-nine per cent (n=25) of the observational studies were at high risk of bias due to lack of reporting on presence/absence of outcome at start of study, attrition rate, and comparability of cohorts based on analysis (whether study adjusted for confounders or not). Thirty-one per cent (n=11) were at low risk of bias. Two RCTs were high risk, four were at an acceptable risk of bias and two were low risk. The main reasons for low quality in RCTs were inadequate reporting on randomisation, concealment, blinding, adequacy and reliability of outcome measurements. For studies which were post hoc observational analysis of RCTs, five were high risk and four were at low risk of bias.

Incidence of bleeding {#s3c}
---------------------

In a cohort of 611 412 participants, 14 217 (2.3%) episodes of bleeds were reported in 34 observational studies and 2685 (2.6%) episodes in a cohort of 103 046 participants in 16 RCTs (714 458 participants overall). A summary of the incidence from each study is presented by length of follow-up, bleeding definition used and in-hospital management strategy in [table 2](#T2){ref-type="table"} for observational studies and [table 3](#T3){ref-type="table"} for RCTs. The overall incidence of bleeding within 12 months post hospital discharge varied from 0.2%[@R44] to 37.5%[@R20] in observational studies, and between 0.96%[@R42] and 39.4%[@R63] in RCTs.

The incidence of bleeding stratified by ACS presentation (STEMI, NSTEMI/UA) and discharge antithrombotic drug combinations and duration (SAPT, DAPT and receipt of oral anticoagulant) are summarised by length of follow-up and the bleeding definition used in online [supplementary tables 3, 4 and 5](#SP1){ref-type="supplementary-material"}. Among those discharged on DAPT with aspirin and a thienopyridine, the incidence of bleeding within the first 12 months based on BARC criteria ranged from 3.91% to 38.8% (see online [supplementary table 4](#SP1){ref-type="supplementary-material"}) in observational studies, and between 0.96% and 47.4% in RCTs (see online [supplementary table 5](#SP1){ref-type="supplementary-material"}).

Eight observational studies[@R23] and two RCTs[@R56] comprising 53 318 participants reported bleeding episodes at different time points during follow-up. In these studies, around one-half of bleeds that occurred in the first year post hospital discharge for ACS happened in the initial 1--3 months ([figure 2](#F2){ref-type="fig"}).

![Cumulative incidence of bleeding as reported within individual studies at different time points (incidence expressed as proportion per 100 persons). BARC, Bleeding Academic Research Consortium; CURE, clopidogrel in unstable angina to prevent recurrent events; HORIZON, harmonising outcomes with revascularisation and stents; OASIS-5, the fifth organisation to assess strategies in acute ischaemic syndromes; TIMI, thrombolysis in myocardial infarction.](bmjopen-2018-023337f02){#F2}

The incidence of major bleeding events in observational studies (based on BARC 3--5) within the first 12 months of hospital discharge was around 1.29%--3.25%. The incidence of minor bleeding events (based on BARC 2) and nuisance bleeds (based on BARC 1) within the same period were around 6.56%--10.6% and 21.9%--37.5%, respectively (see [figure 3](#F3){ref-type="fig"} and online [supplementary table 6](#SP1){ref-type="supplementary-material"}). Generally, bruising (defined as skin haematoma, ecchymosis, petechiae) were the most commonly reported types of bleeding events post hospital discharge (range: 1.49%--22.5% within 12 months) followed by gastrointestinal bleeds (range: 0.25%--7.63% within 12 months; see [figure 4](#F4){ref-type="fig"} and online [supplementary table 7](#SP1){ref-type="supplementary-material"}).

![Incidence of bleeding stratified by severity in observational studies that reported bleeding by Bleeding Academic Research Consortium (BARC) criteria within the first 12 months after hospital discharge.](bmjopen-2018-023337f03){#F3}

![Incidence of each type of bleeding event within the first 12 months after hospital discharge in observational studies.](bmjopen-2018-023337f04){#F4}

Bleeding and risk of mortality {#s3d}
------------------------------

There was consistent reporting of an association between postdischarge bleeding and all-cause mortality in five observational studies[@R39] and one RCT[@R53] ([table 4](#T4){ref-type="table"}). Major bleeding was associated with nearly threefold increased risk of mortality in the first 12 months of hospital discharge in two studies ([table 4](#T4){ref-type="table"}).[@R47] Nuisance bleeding events defined as BARC 1 were not associated with mortality in one RCT, but there was an increased risk of mortality with BARC 2 and 3 bleeds in the same RCT,[@R53] which increased with bleeding severity ([table 4](#T4){ref-type="table"}). The SOE for the outcome of mortality was rated low (online [supplementary table 8](#SP1){ref-type="supplementary-material"}).

Bleeding and risk of MACE, rehospitalisation and re-infarction {#s3e}
--------------------------------------------------------------

The adjusted (adj) risk (HR) of MACE with bleeding (defined as bleeds leading to hospitalisation or death) was 3.00 (95% CI 2.75 to 3.27 in one study; [table 4](#T4){ref-type="table"}).[@R40] There was a statistically non-significant association between postdischarge bleed (defined as BARC 1 bleeds) and risk of rehospitalisation (adj HR 1.20, 95% CI 0.95 to 1.52 in another study; [table 4](#T4){ref-type="table"}).[@R20] There were no studies examining the association between postdischarge bleeding and subsequent risk of re-infarction. The SOE for the outcomes of MACE and rehospitalisation were rated insufficient (online [supplementary table 8](#SP1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

Our systematic review is the first to study the incidence, timing and types of postdischarge bleeding complications, and their association with mortality, MACE, re-infarction and rehospitalisation. Fifty-three studies were included, comprising 36 observational studies and 17 RCTs with a combined cohort of 714 458 participants for the primary objectives and 187 317 for the secondary objectives. We report that bleeding complications post-ACS are common following hospital discharge, and vary by length of follow-up, severity, type and the definition of bleeding used. We report that the incidence of bleeding was highest in the initial 3 months after hospital discharge for ACS, with bleeding events continuing to occur even after 1-year postdischarge. The majority of postdischarge bleeding events were nuisance bleeds such as ecchymosis and petechiae, with major bleeding events such as intracranial haemorrhage less common. While there was substantial heterogeneity between studies, we report that up to one-third of patients discharged on DAPT will experience bleeding complications in the first 12 months after hospital discharge, and around 1.3%--3.3% of patients will experience a major bleed.

Our review shows that major bleeding may increase the risk of mortality by nearly threefold in the first 12 months after hospital discharge, but the strength of the evidence was weak. We identified very limited data on whether postdischarge bleeding was associated with MACE and rehospitalisation. Although there was an indication of an association with MACE in one study[@R40] and rehospitalisation in another,[@R20] the latter association did not reach statistical significance.

Clinical implications {#s4a}
---------------------

Although current guidelines[@R71] have recommended dual therapy with aspirin and a thienopyridine for up to 12 months and triple therapy in the presence of comorbid conditions such as atrial fibrillation for shorter periods, it was evident from our study that these maintenance therapies are accompanied by bleeding complications which predominantly occur post hospital discharge. Consideration must therefore be given to ways of minimising these bleeding complications, such as by encouraging clinicians to use risk scoring algorithms such as DAPT,[@R74] precise-DAPT,[@R75] BleeMACS score[@R76] (for patients with ACS treated with PCI) or TRILOGY-ACS bleeding risk model[@R77] (for patients with NSTEMI/UA managed medically) to identify patients at higher risk of these bleeding complications, such that maintenance oral antithrombotics or newer oral anticoagulants that have more favourable safety profile than warfarin can be tailored to fit each patient's risk profile. However, it must be borne in mind that many of these risk algorithms were developed in the clinical trial setting, and have not yet been validated in unselected cohorts. Aspirin regardless of dose increases the risk of gastrointestinal bleeds.[@R78] In high-risk patients such as those with previous history of these types of bleeds, concomitant use of a proton pump inhibitor as advocated by the European Society of Cardiology guidelines will reduce the future risk of these bleeds.[@R80]

Research implications {#s4b}
---------------------

The majority of studies in this review were not primarily designed to investigate the incidence of bleeding complications. This meant that incidences could only be reported here as per 100 persons, that is, essentially as a proportion, rather than per 100 persons years at risk. This underscores the need to examine the incidence of these bleeding events using high-quality observational studies that are more reflective of the real-world populations encountered in clinical practice. The incidence of postdischarge bleeding complications may vary by type of bleed, patient demographics and discharge pharmacotherapy. Future studies should explore factors associated with postdischarge bleeding complications so that risk stratification tools that are more representative of the unselected cohorts encountered in clinical practice (often ignored in RCTs) can be developed to identify individuals at high risk of bleeding post hospital discharge, as most contemporary bleeding risk scores predict in-hospital bleeding events.[@R81]

We also report that bleeding complications post hospital discharge may be associated with subsequent risk of mortality, although evidence from the literature was limited. The risks of MACE and rehospitalisation were only reported in two studies, and none of the studies in the review reported on re-infarction. Future research is required to quantify these associations, with particular emphasis on whether nuisance and minor bleeding events that are much more common post hospital discharge also have a prognostic impact. Finally, future research examining these associations should stratify by the timing of the bleeding events in order to determine whether the prognostic impacts of these bleeding complications are more pronounced in the early phases of hospital discharge or are equally important in the long term after hospital discharge.

Limitations of the review {#s4c}
-------------------------

This study has several potential limitations. First, the studies included in the review were too heterogeneous in regard to bleeding definition, ACS presentation, demographic characteristics of the study participants, severity and type of bleeding examined, length of follow-up, discharge antiplatelet and anticoagulant regimens to pool data to obtain an overall incidence and mortality figures. Second, the duration and dosage of discharge antithrombotic therapy as well as in-hospital management strategies were not specified in the majority of studies (due to selective reporting), as such we were unable to adequately assess the impact of these factors on the incidence of bleeding. In the majority of studies, episodes of bleeds were extracted to calculate incidence figures. In most of these studies, there was lack of clarity on whether patients were included in the numerator more than once if they had multiple episodes of bleeds. However, since bleeding complications are rare events[@R5] and having more than one episode of bleeding is even rarer, it is unlikely that this would have affected the overall incidence. Similarly, for some studies where episodes of bleeds were reported at different time intervals and the number of people at risk within each time interval were not reported, incidence figures were estimated based on the assumption that there was no attrition, hence these figures may have been underestimated.

Conclusions {#s5}
===========

In this systematic review of 53 studies, bleeding complications post hospital discharge for ACS were found to be common, with bruising the most common. These bleeding complications vary by severity, anatomic source and type of discharge antithrombotic therapy, and while most common immediately postdischarge, these bleeds continue to occur in the long term. There are limited data around the long-term outcomes of patients that sustain bleeding events post hospital discharge for ACS. Further work is required to define the nature, frequency and prognostic impact of such bleeding events, using formal bleeding definitions. Real-world risk stratification tools will need to be developed that specifically predict the risk of bleeding complications postdischarge to identify high-risk individuals for a more patient-centred approach in managing optimal pharmacotherapy and care.
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